Wang B, Zhang L, Hu S, et al. - Researchers examined the link between use of angiotensin receptor blocker (ARB) and 1 year all‐cause mortality following hospitalization for heart failure with mid‐range ejection fraction (HFmrEF), in this study with 701 patients (mean age was 66.4 ± 12.8 years, and 267 (38.1%) were women). Data were studied for patients exhibiting an ejection fraction of 40–49% in China Patient‐centred Evaluative Assessment of Cardiac Events Prospective Heart Failure Study; enrollment of 4,907 patients hospitalized for heart failure from 52 Chinese hospitals was done from August 2016 to May 2018. A total 244 of 701 patients received treatment (34.8%) with ARB. According to findings, a lower 1 year mortality post-discharge was observed in relation to ARB use in patients hospitalized for HFmrEF.